Ym Biosciences Australia Pty Ltd.

Cytopia Research Pty Ltd

Michelle Leanne Styles

Andrew Frederick Wilks

Christopher John Burns

Xianyong Bu

Jun Zeng

Emmanuelle Fantino

Herbert Rudolf Treutlein

Marcel Robert Kling

Jamie Rossjohn

Isabelle Lucet

A compound of the general formula (I) or pharmaceutically acceptable prodrugs, salts, hydrates, solvates, crystal forms or diastereomers thereof, wherein A represents a variety of six membered nitrogen containing heterocyclic rings, Q is a bond, halogen, Calkyl, O, S, SO, CO or CS and X, X, Xand Xare optionally substituted by 9 specific substituents or one can be nitrogen. Compositions comprising a carrier and at least one compound of formula (I) are also provided. Further provided are methods of treating tyrosine kinase-associated disease states by administering a compound of formula (I) and methods of suppressing the immune system of a subject by administering a compound of formula (I). 

Benzimidazoles as selective kinase inhibitors

The present invention relates to X-ray crystallography studies of a human Janus Kinase 2 (JAK2) domain. More particularly, it relates to the crystal structure of a JAK2 kinase domain bound to a inhibitor. The invention further relates to the use of the crystal and related structural information to select and screen for compounds that interact with JAK2 and related proteins and to compounds that could be used for the treatment of diseases mediated by inappropriate JAK2 activity.

Crystal structure of human Janus Kinase 2 (JAK2) and uses thereof

Growing community of inventors

London, United Kingdom

Michelle Leanne Styles